The development of an innovative imaging agent capable of non-invasively detecting vulnerable plaques is a major goal of research in cardiovascular pathology. Such a tool would allow better identification of patients at risk for acute cardiovascular…
ID
Bron
Verkorte titel
Aandoening
Fucoidan; P-selectin; cardiovascular disease; atherosclerosis; thrombosis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Tolerability will be evaluated on the frequency and severity of adverse events, as well as on the following parameters: <br>
- Vital signs<br>
- Physical examination<br>
- ECG <br>
- Clinical blood laboratory measurements
Achtergrond van het onderzoek
The development of an innovative imaging agent capable of non-invasively detecting
vulnerable plaques is a major goal of research in cardiovascular pathology. Such a tool
would allow better identification of patients at risk for acute cardiovascular events. We have
shown that 99mTechnetium-labeled (99mTc) Fucoidan can target P-selectin expressed by in
vitro activated human platelets and in vivo in an animal model of aortic thrombosis as well as
endocarditis. One of the objectives of the Nanoathero program is the clinical translation of
99mTc-Fucoidan scintigraphy. First, we will study the tolerability and the dosimetric evaluation
of this new radiopharmaceutical in humans.
Doel van het onderzoek
The development of an innovative imaging agent capable of non-invasively detecting vulnerable plaques is a major goal of research in cardiovascular pathology. Such a tool would allow better identification of patients at risk for acute cardiovascular events. We have shown that 99mTechnetium-labeled (99mTc) Fucoidan can target P-selectin expressed by in vitro activated human platelets and in vivo in an animal model of aortic thrombosis as well as endocarditis. One of the objectives of the Nanoathero program is the clinical translation of 99mTc-Fucoidan scintigraphy. First, we will study the tolerability and the dosimetric evaluation of this new radiopharmaceutical in humans.
Onderzoeksopzet
After injection of 99mTc-Fucoidan, t=30min, 1.5h, 3h, 6h, 24h and 7d
Onderzoeksproduct en/of interventie
99mTc-Fucoidan SPECT/CT
Publiek
K.H. Zheng
Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+31 20 5667516
k.h.zheng@amc.nl
Wetenschappelijk
K.H. Zheng
Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+31 20 5667516
k.h.zheng@amc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Adult subjects of either gender, aged 18 years or older
- BMI between 18 and 35 kg/m2
- Effective contraception in women of childbearing age
- Use of effective contraception in men for 24 hours after injection of 99mTc-Fucoidan
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Progressive and chronic disease
- Chronic infection with HIV, HBV or HCV
- Clinically significant abnormalities during screening
- Pregnancy or breast-feeding
- Active medication use or previous long-term intake of medication
- Any other treatment that could interfere with the conduct or interpretation of the study in the opinion of the investigator
- Any other clinically relevant condition that could interfere with the conduct of the study in the opinion of the investigator
- Standard contra-indications to SPECT/CT
- Inability or unwilling to comply with protocol requirements, or deemed by the investigator to have a disorder that may compromise the ability to give informed
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6703 |
| NTR-old | NTR6873 |
| Ander register | METC AMC Amsterdam : 2017_321 |